MedPath

Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography

Phase 4
Terminated
Conditions
High Altitude Pulmonary Edema
Interventions
Drug: Placebo
Registration Number
NCT03490916
Lead Sponsor
Vincent Kan
Brief Summary

The overall goal of this study is to detect preclinical signs of HAPE by lung ultrasonography and evaluate the effectiveness of acetazolamide at decreasing pulmonary edema by using ultrasound.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
18
Inclusion Criteria
  1. At least 18 years of age
  2. Able to consent
  3. English speaking
  4. Trekking directly to Everest Base Camp
Exclusion Criteria
  1. Age less than 18 years
  2. Non-English speaking
  3. Pregnant
  4. Already had a diagnosis of acute mountain sickness, high-altitude cerebral edema, or high-altitude pulmonary edema
  5. Been on a high-altitude trek 2 weeks prior to this study
  6. Has taken acetazolamide 1 week prior to start of trek
  7. Has a sulfa allergy
  8. Has any type of acute or chronic pulmonary conditions

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Acetazolamide normal doseAcetazolamideOne (1) dose of 250mg of Acetazolamide
PlaceboPlaceboOne (1) dose of placebo
Primary Outcome Measures
NameTimeMethod
Pulmonary Edema Before and After Taking Acetazolamide1 month

Edema measured through ultrasound exam

Secondary Outcome Measures
NameTimeMethod
Time to Completion of Ultrasound Exams1 month

Time it takes to complete ultrasound exams

Trial Locations

Locations (1)

UMass Medical School

🇺🇸

Worcester, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath